drugset / Trial / NCT03149419

Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments

NCT03149419

Phase 4 Completed 140 enrolled Rio de Janeiro State University
RandomizedParallel-groupDouble-blindTreatment

Summary

Hot flashes, vasomotor symptoms that affect many postmenopausal women, are associated with cardiovascular disease and endothelial dysfunction. Estrogen therapy, associated or not with progestogens, is the standard treatment for vasomotor symptoms and improves the endothelial function of postmenopausal women with hot flushes, even those with cardiovascular risk factors, such as hypertension. It is not known whether hot flushes are a cause for the development of endothelial dysfunction or are markers of this dysfunction, evidenced by estrogen deficiency, thus representing primitive target organ (vessel) lesion. Paroxetine was approved by the FDA as a non hormonal treatment for menopausal hot flashes. In this double-blind randomized clinical trial, the vascular effects of paroxetine at a dose of 7.5 mg / day, compared to placebo, during 12 weeks are evaluated.

Timeline

Start
2016-03-01
Primary completion
2017-09-30
Completion
2018-03-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Paroxetine Small molecule 7.5 mg Oral